1. Emerging Paradigms in ALK-Positive NSCLC

2. Introduction

3. ALK TKIs Available/Ongoing Investigation

4. Relative Efficacy of ALTA vs Comparators

5. Safety Profile of ALK Inhibitors in the Post Crizotinib Setting

6. Early Onset Pulmonary Events With Brigatinib

7. Classical EOPE Timing of Onset and Offset

8. Summary of Second-Line Discussion

9. Summary of Second-Line Discussion (cont)

10. ALEX: Alectinib vs Crizotinib as First-Line Therapy

11. ALTA-1L: Brigatinib vs Crizotinib in the First-Line

12. Alectinib: PFS by CNS Metastatic Status

13. Intracranial PFS by IRC

14. Median Duration of Follow Up Only 9 to 11 Months in ALTA-1L to Date - Extracranial PFS Differences yet to Fully Realize

15. Summary of First-Line Data

16. Abbreviations